Skip to main content
SpringerLink
Log in

Targeting mutant p53 through the mevalonate pathway

  • News & Views
  • Published:

From Nature Cell Biology

View current issue Submit your manuscript

It is well established that mutant forms of the p53 tumour suppressor acquire pro-oncogenic activities. Inhibition of the mevalonate pathway is now shown to promote degradation of select oncogenic mutant p53 proteins, indicating that destabilization of mutant p53 could be a promising therapeutic strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Mutant p53 and the mevalonate pathway feed-forward loop in oncogenesis.

References

  1. Vousden, K. H. & Prives, C. Cell 137, 413–431 (2009).

    CAS  Google Scholar 

  2. Brosh, R. & Rotter, V. Nat. Rev. Cancer 9, 701–713 (2009).

    Article  CAS  Google Scholar 

  3. Freed-Pastor, W. A. & Prives, C. Genes Dev. 26, 1268–1286 (2012).

    Article  CAS  Google Scholar 

  4. Alexandrova, E. M. et al. Nature 523, 352–356 (2015).

    Article  CAS  Google Scholar 

  5. Terzian, T. et al. Genes Dev. 22, 1337–1344 (2008).

    Article  CAS  Google Scholar 

  6. Parrales, A. et al. Nat. Cell Biol. 18, 1233–1243 (2016).

    Article  CAS  Google Scholar 

  7. Mullen, P. J., Yu, R., Longo, J., Archer, M. C. & Penn, L. Z. Nat. Rev. Cancer http://doi.org/brjq (2016).

  8. Wiech, M. et al. PloS ONE 7, e51426 (2012).

    Article  CAS  Google Scholar 

  9. Lukashchuk, N. & Vousden, K. H. Mol. Cell. Biol. 27, 8284–8295 (2007).

    Article  CAS  Google Scholar 

  10. Krönke, J. et al. Science 343, 301–305 (2014).

    Article  Google Scholar 

  11. Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P. & Anderson, K. C. Mol. Cancer Ther. 4, 686–692 (2005).

    Article  CAS  Google Scholar 

  12. Walerych, D. et al. Nat. Cell Biol. 18, 897–909 (2016).

    Article  CAS  Google Scholar 

  13. Xu, J. et al. Nat. Chem. Biol. 7, 285–295 (2011).

    Article  CAS  Google Scholar 

  14. Freed-Pastor, W. A. et al. Cell 148, 244–258 (2012).

    Article  CAS  Google Scholar 

  15. Sorrentino, G. et al. Nat. Cell Biol. 16, 357–366 (2014).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. William Freed-Pastor is at the Dana Farber Cancer Institute, 450 Brookline Ave, Boston, Massachusetts 12215, USA,

    William Freed-Pastor

  2. Carol Prives is in the Department of Biological Sciences, Columbia University, New York, New York 10027, USA,

    Carol Prives

Authors
  1. William Freed-Pastor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol Prives
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to William Freed-Pastor or Carol Prives.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Freed-Pastor, W., Prives, C. Targeting mutant p53 through the mevalonate pathway. Nat Cell Biol 18, 1122–1124 (2016). https://doi.org/10.1038/ncb3435

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncb3435

  • Springer Nature Limited

This article is cited by

Search

Navigation